PlainPharmaWatch

CMS Open Payments · Program Year 2024

Pharma payments to doctors, transparent and searchable.

$13.9B paid by 1,925 pharmaceutical and medical-device companies to 988,644 physicians and 916 teaching hospitals in Program Year 2024 - General Payments, Research, and Ownership combined.

Search company payments → About this data
Quick browse Guides By state Rankings Compare Research

Total payments

$13.9B

All tracks · PY 2024

Companies

1,925

Pharma & device makers

Physicians

988,644

Receiving payments

Transactions

16,654,614

Individual payments

Directory totals above combine CMS General Payments ($3.4B across 1,838 companies with a nature-of-payment category) with Research and Ownership ($10.5B). Category charts below use the General Payments subset only - see methodology.

In CMS Open Payments Program Year 2024, 1,925 pharmaceutical and medical-device companies reported $13.9B in payments to 988,644 physicians and teaching hospitals. Novartis Pharmaceuticals Corporation reported the most, and the largest payment category was Royalty or License. Explore the data by company, state, or payment type, figures are company-reported under the Physician Payments Sunshine Act, not evidence of wrongdoing.

The national picture

Pharmaceutical and medical-device makers reported $13.9B in payments to physicians and teaching hospitals in 2024, led by royalty or license.

$13.9B
total industry payments
1,925
reporting companies
988,644
recipients paid
16,654,614
transactions

General Payment Type Breakdown

Shares are of $3.4B in CMS General Payments only. Research and Ownership ($10.5B) are outside these categories.

Royalty or License $855.1M (25.0%)
Compensation for Services Other Than Consulting $706.0M (20.6%)
Consulting Fee $573.8M (16.8%)
Food and Beverage $415.1M (12.1%)
Acquisitions $266.2M (7.8%)
Travel and Lodging $207.8M (6.1%)
View all payment types

Top Companies by Total Payments

View all
# Company Total Payments Transactions
1 Novartis Pharmaceuticals Corporation $676.0M 418,352
2 Pfizer Inc. $673.7M 606,504
3 ModernaTX, Inc. $665.3M 31,546
4 Eli Lilly and Company $652.4M 21,268
5 Abbvie Inc. $607.8M 1,766,164
6 Merck Sharp & Dohme LLC $525.2M 223,349
7 AstraZeneca Pharmaceuticals LP $428.2M 864,383
8 Genentech, Inc. $400.6M 36,410
9 Midmark Corporation $386.1M 381
10 Janssen Research & Development, LLC $345.1M 40,226

Payment Concentration: Where the Money Goes

Among the 25 largest payers, total spending doesn't say how many physicians actually received it. The Herfindahl-Hirschman Index (HHI) measures concentration: a low HHI means payments are spread across many recipients, a high HHI means a small number (sometimes one) receive most or all of it. 2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated."

19.361.6104.0146.3188.7025005000750010000Total payments ($M)Concentration (HHI, 0-10,000)BioNTech SE, Total payments ($M): 181 · Concentration (HHI, 0-10,000): 9959Abbvie Inc., Total payments ($M): 157 · Concentration (HHI, 0-10,000): 57Stryker Corporation, Total payments ($M): 135 · Concentration (HHI, 0-10,000): 67Medtronic, Inc., Total payments ($M): 118 · Concentration (HHI, 0-10,000): 247Arthrex, Inc., Total payments ($M): 104 · Concentration (HHI, 0-10,000): 439DePuy Synthes Products, Inc., Total payments ($M): 101 · Concentration (HHI, 0-10,000): 1338Edge Endo LLC, Total payments ($M): 91 · Concentration (HHI, 0-10,000): 9988Zimmer Biomet Holdings, Inc., Total payments ($M): 84 · Concentration (HHI, 0-10,000): 1031Intuitive Surgical, Inc., Total payments ($M): 74 · Concentration (HHI, 0-10,000): 18Takeda Pharmaceuticals U.S.A., Inc., Total payments ($M): 73 · Concentration (HHI, 0-10,000): 1650AstraZeneca Pharmaceuticals LP, Total payments ($M): 65 · Concentration (HHI, 0-10,000): 22Advanced Accelerator Applications, Total payments ($M): 64 · Concentration (HHI, 0-10,000): 10000Boston Scientific Corporation, Total payments ($M): 62 · Concentration (HHI, 0-10,000): 45Genentech, Inc., Total payments ($M): 59 · Concentration (HHI, 0-10,000): 6977Genzyme Corporation, Total payments ($M): 58 · Concentration (HHI, 0-10,000): 783Lilly USA, LLC, Total payments ($M): 47 · Concentration (HHI, 0-10,000): 16Smith+Nephew, Inc., Total payments ($M): 46 · Concentration (HHI, 0-10,000): 151Amgen Inc., Total payments ($M): 45 · Concentration (HHI, 0-10,000): 55Pfizer Inc., Total payments ($M): 44 · Concentration (HHI, 0-10,000): 22Gilead Sciences, Inc., Total payments ($M): 40 · Concentration (HHI, 0-10,000): 168Abbott Laboratories, Total payments ($M): 38 · Concentration (HHI, 0-10,000): 23E.R. Squibb & Sons, L.L.C., Total payments ($M): 31 · Concentration (HHI, 0-10,000): 12Janssen Biotech, Inc., Total payments ($M): 31 · Concentration (HHI, 0-10,000): 13Edwards Lifesciences Corporation, Total payments ($M): 28 · Concentration (HHI, 0-10,000): 353Henry Schein, Inc., Total payments ($M): 27 · Concentration (HHI, 0-10,000): 9520
Total payments vs. recipient concentration among the top 25 companies by spending, PY2024. Dashed lines mark the median payment total and the DOJ/FTC "highly concentrated" threshold. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).

Payments by State

Total reported pharmaceutical payments across all 59 states and territories, Program Year 2024.

Total pharmaceutical payments by state, PY2024
AK ME
VT NH
WA ID MT ND MN IL WI MI NY MA
OR UT WY SD IA IN OH PA NJ CT RI
CA NV CO NE MO KY WV VA MD DE
AZ NM KS AR TN NC SC DC
OK LA MS AL GA
HI TX FL
Scale: $165–$68.5M $68.5M–$137.0M $137.0M–$205.4M $205.4M–$273.9M $273.9M–$342.4M
View all 59 states as a list
  1. California: $342.4M
  2. Florida: $334.6M
  3. Pennsylvania: $305.4M
  4. Massachusetts: $230.3M
  5. Texas: $224.7M
  6. New York: $216.8M
  7. Missouri: $121.9M
  8. Illinois: $120.3M
  9. Ohio: $112.1M
  10. Georgia: $107.1M
  11. Michigan: $101.8M
  12. North Carolina: $97.2M
  13. Tennessee: $81.9M
  14. Virginia: $80.6M
  15. Arizona: $67.8M
  16. New Jersey: $64.8M
  17. Colorado: $63.4M
  18. Washington: $59.1M
  19. Maryland: $54.7M
  20. Minnesota: $50.1M
  21. Indiana: $49.5M
  22. Alabama: $36.5M
  23. Connecticut: $35.3M
  24. South Carolina: $35.1M
  25. Kentucky: $35.0M
  26. Utah: $34.7M
  27. Kansas: $33.6M
  28. Louisiana: $33.4M
  29. Hawaii: $32.9M
  30. Wisconsin: $30.5M
  31. Nevada: $27.8M
  32. District of Columbia: $26.4M
  33. Oklahoma: $24.3M
  34. Oregon: $19.9M
  35. Iowa: $17.6M
  36. Mississippi: $15.2M
  37. Arkansas: $13.3M
  38. Idaho: $12.2M
  39. New Hampshire: $9.4M
  40. Nebraska: $9.3M
  41. West Virginia: $8.3M
  42. Rhode Island: $8.0M
  43. PR: $7.5M
  44. South Dakota: $7.3M
  45. New Mexico: $6.7M
  46. Delaware: $4.3M
  47. Maine: $3.5M
  48. Montana: $2.8M
  49. North Dakota: $1.8M
  50. Alaska: $1.6M
  51. Wyoming: $1.6M
  52. Vermont: $1.5M
  53. AE: $97K
  54. AP: $74K
  55. VI: $18K
  56. GU: $13K
  57. AS: $732
  58. MP: $659
  59. AA: $165

Top States by Payments Received

View all
# State Total Payments Physicians
1 California $342.4M 75,013
2 Florida $334.6M 54,303
3 Pennsylvania $305.4M 31,976
4 Massachusetts $230.3M 16,112
5 Texas $224.7M 58,838
6 New York $216.8M 49,928
7 Missouri $121.9M 14,854
8 Illinois $120.3M 29,359
9 Ohio $112.1M 27,813
10 Georgia $107.1M 22,488

Top Highlights

CA$289M$34MFL$297MPA$98M$198MMA$75M$152MTX$185M$19MNY$185M$17MMO$51M$66MIL$98M$15MPhysiciansHospitals
Top 8 states, PY2024 payments to physicians vs teaching hospitals (USD millions). Source: CMS Open Payments.

Total payments PY2024

$13.9B

16,654,614 transactions

Physicians paid

988,644

916 teaching hospitals

Share of General Payments from largest category - Royalty or License 25.0%

$855.1M of $3.4B General Payments (25.0%)

Learn About Open Payments

Educational guides on the Sunshine Act, payment types, and how transparency data can inform your healthcare decisions.

Understanding Open Payments

What the Sunshine Act requires and how CMS collects payment data.

Pharma Payment Types

Research, consulting, speaking, and food payments, what each means.

Why Transparency Matters

What research shows about payments and prescribing patterns.

How Much Pharma Spends on Doctors

$13.9B in PY2024, breakdown by category, trends, and top companies.

Drug Company Marketing Practices

Speaker bureaus, consulting fees, advisory boards, how pharma shapes prescribing.

About this data

How PlainPharmaWatch works, and why you can trust these numbers

What this site is

PlainPharmaWatch turns the CMS Open Payments program into searchable payment profiles for pharmaceutical and device companies. Every dollar amount is taken directly from CMS data without adjustment, inflation correction, or statistical modeling.

Editorial process

  1. Source. Process the official CMS Open Payments detailed publication: General Payments plus Research and Ownership records, with company, state, payment-type, and recipient aggregates derived reproducibly.
  2. Verify. Company profiles show exactly what was reported to CMS for program year 2024, the latest CMS has released, with no adjustment applied.
  3. Publish. Compile per-company and per-state payment breakdowns, linking back to the CMS Open Payments dataset so readers can verify any figure.

Editorial independence & corrections

PlainPharmaWatch is an independent publisher; it does not accept payment, sponsorship, or promoted placement from any pharmaceutical or device company covered on the site. Found an error? Contact us via the contact page or our editorial policy. See our methodology for full source attribution.

Frequently asked

What data does PlainPharmaWatch provide?

PlainPharmaWatch provides CMS Open Payments data showing pharmaceutical company payments to doctors, covering 1,925 companies and totaling $13.9B across General Payments, Research, and Ownership tracks in payment year 2024. Category charts use the General Payments subset ($3.4B).

What types of payments are reported?

Payments include consulting fees, speaking fees, travel, meals, research grants, and ownership interests. Each payment is categorized by type and amount.

Where does the data come from?

All data comes from the CMS Open Payments program, which requires drug and device manufacturers to publicly report payments made to physicians and teaching hospitals.

Published by PlainPharmaWatch
Primary sources CMS Open Payments

Data current as of program year 2024, from the processed CMS detailed publication

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Frequently Asked Questions

What data does PlainPharmaWatch provide?

PlainPharmaWatch provides CMS Open Payments data showing pharmaceutical company payments to doctors, covering 1,925 companies and totaling $13.9B across General Payments, Research, and Ownership tracks in payment year 2024. Category charts use the General Payments subset ($3.4B).

What types of payments are reported?

Payments include consulting fees, speaking fees, travel, meals, research grants, and ownership interests. Each payment is categorized by type and amount.

Where does the data come from?

All data comes from the CMS Open Payments program, which requires drug and device manufacturers to publicly report payments made to physicians and teaching hospitals.

Live Data Products

Every page renders directly from the current CMS Open Payments database, no curated narrative layer that could drift from the underlying dataset. See methodology.

Live Data

Company Payment Summaries

Per-company total payments, transaction counts, and recipient coverage across all reporting applicable manufacturers in the CMS Open Payments database.

1,925companies tracked

 Live Data

Top Recipients Directory

Highest-paid teaching hospitals, physicians, and other covered recipients from the current Program Year dataset.

 Live Data

Payment Type Breakdowns

Aggregated totals by Nature of Payment category, consulting fees, food and beverage, royalties, and education.